> Carl Icahn may have won the ImClone war, but Bristol-Myers Squibb counts itself among the victors, too. Though Bristol won't get control of ImClone, it will rake in about $1 billion in cash for its 17 percent stake when Eli Lilly forks over the $70 a share buyout price. Report
> Anxious to push ahead with a slate of early-stage therapies, Eli Lilly struck a deal with India's Jubilant--a clinical research organization and manufacturer--to create a joint venture discovery firm. The venture will provide preclinical and early-stage discovery work, advancing therapies to Phase II testing before returning them for more advanced research work. Report
> Alnylam has earned a $20 million milestone payment from Takeda. The two companies forged a pact on RNAi technology. Alnylam release
> The Malaysian Biotechnology Corp. announced that India's Malladi Drugs & Pharmaceutical will invest up to $300 million over the next 3 to 5 years to set up its global "one-stop shop" in Malaysia. Report
> Bavarian Nordic says that positive results from a Phase II trial has opened the door to confirmatory Phase III studies for PROSTVAC in the first half of 2010. Bavarian Nordic release
> Ironwood Pharmaceuticals and Forest Laboratories have presented positive results from a Phase IIb study assessing linaclotide's safety and efficacy in 420 patients with irritable bowel syndrome with constipation. The data indicated that linaclotide significantly reduced abdominal pain and significantly improved constipation symptoms in patients with IBS-C. Ironwood release
> After rejecting King's sweetened takeover bid, Alpharma says it will negotiate with King, at least privately; the company told the Securities and Exchange Commission that it's inking a confidentiality agreement with its previously rebuffed partner. Report
> Genentech and Biogen Idec are crowing today about Rituxan's performance in a leukemia trial. Report
> Myriad Genetics announced today that it has acquired the exclusive North American license to specific application of novel proprietary technology used to perform pharmacokinetic analysis of therapeutic drugs in patients. Myriad release
> Philanthropist Lorry Lokey is giving Stanford University School of Medicine $75 million of his fortune to help pay for a $200 million stem cell research center that will bear his name. Report
> An expert panel formed by the University of Minnesota has determined that a PhD student who worked with a team of researchers responsible for a high-profile study involving adult stem cells extracted from bone marrow falsified data in an earlier research report. Report
> An experimental anti-cancer drug can prevent--and even reverse--potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, NIH researchers reported today. Report
And Finally... A study led by researchers at the University of California, San Diego School of Medicine suggests that use of oral Vitamin D supplements bolsters production of a protective chemical normally found in the skin, and may help prevent skin infections that are a common result of atopic dermatitis, the most common form of eczema. Release